Ozempic and eating disorders: what to know

Semaglutide is the medication sold as Ozempic (approved for type 2 diabetes) and Wegovy (approved for weight management). It belongs to a class called GLP-1 receptor agonists, which lower appetite and slow how quickly the stomach empties.¹ For some people with a medical need, these drugs are an appropriate, prescribed treatment. For people with an eating disorder, a history of one, or a vulnerability to disordered eating, the same effects that make the medication work can become dangerous.

This page explains how semaglutide interacts with eating disorders, who is most at risk, the warning signs to watch for, and what to do. It is written for people taking or considering these medications, and for the family members who are worried about someone who is.

How the medication interacts with eating disorders

GLP-1 medications work largely by reducing appetite and increasing the feeling of fullness, as the FDA labeling describes.¹ In a person without an eating disorder, that can support medically supervised weight management. In a person with restrictive eating, the same appetite suppression can reinforce the very behavior the eating disorder is built on. The drug makes eating less, restriction, and rapid weight loss easier to sustain, and it can mask the hunger cues that recovery works to rebuild.

Eating disorder clinicians, including the National Eating Disorders Association, have raised specific concerns as these medications have become widely prescribed:²

• Appetite suppression can entrench restriction. For someone with anorexia or atypical anorexia, a drug that removes hunger can worsen the illness rather than treat it.
• Rapid weight loss is a known trigger. Fast or dramatic weight loss can precipitate or worsen an eating disorder in vulnerable people, regardless of how the loss happens.
• The drugs can be misused. People with eating disorders sometimes obtain these medications specifically to lose weight, outside of any legitimate medical indication.
• Recovery cues are blunted. Nutritional rehabilitation depends on relearning hunger and fullness. A medication that suppresses both works against that process.

The research picture is still developing, and there is active scientific interest in whether GLP-1 medications might help some people with binge eating disorder.³ That question is not settled, these uses are not FDA-approved, and the existence of a research question does not make the medication safe for someone with an active eating disorder. Decisions like this belong with a clinician who knows the person's full history.

What the research shows

The science here is young and still moving, so it helps to be precise about what is and is not known.

On the risk side, the concern is mechanistic and clinical rather than the product of large long-term trials in people with eating disorders. GLP-1 medications were studied and approved for type 2 diabetes and for weight management, not for use in people with a history of disordered eating, who are typically excluded from those trials.¹ What clinicians report is that the medications' core effects, strong appetite suppression and rapid weight loss, are the same forces known to trigger or sustain restrictive eating in vulnerable people.²

On the treatment side, there is genuine research interest in whether GLP-1 medications might help some people with binge eating disorder, since reducing appetite and the drive to eat could in theory lower binge frequency. The studies so far are small and short, the medications are not FDA-approved for binge eating disorder, and binge eating disorder already has established, evidence-based treatments that should come first.³ A research signal is not a treatment recommendation.

Taken together: there is real reason for caution and little high-quality evidence of benefit for people with eating disorders. The decision belongs with a clinician who knows the person's full history.

Who is most at risk

The concern is highest for:

• Anyone with a current eating disorder of any type, including binge eating disorder
• Anyone with a history of an eating disorder, even one considered resolved
• People with a history of chronic dieting, weight cycling, or a difficult relationship with food and body image
• Adolescents and teens, whose growing bodies and higher baseline eating-disorder risk make weight-loss medication a distinct concern (covered in our companion article on GLP-1 medications and teens)
• People obtaining the medication without medical supervision, including through online or compounded sources

A prescribing clinician should always be told about any eating disorder history before these medications are started. That history can change the calculation entirely.

Warning signs that use has become disordered

The line between prescribed, supervised use and disordered use is not always obvious. Signs that warrant a conversation with a professional include:

A fuller list is in our guide on the signs that weight-loss medication use has become disordered. If any of these are present, it is worth talking to someone. Our self-assessment is one private place to start, though it is a screen and not a diagnosis.

What to do

If you are taking semaglutide and recognize these patterns in yourself, or you are worried about someone who is, the next step is a conversation with a qualified professional. That can be the prescribing clinician, a primary care doctor, or an eating disorder specialist. Do not stop a prescribed medication abruptly without medical advice, but do raise the concern.

A few questions make that conversation more useful:

• Does my history of disordered eating or chronic dieting change whether this medication is safe for me?
• How will we watch for restrictive eating, rapid weight loss, or returning eating disorder behaviors while I take it?
• What is the plan if I want to stop, and how do we handle distress or rebound around weight?
• Are there approaches to my health goal that carry less eating-disorder risk?

If an eating disorder is part of the picture, treatment works. You can read about the conditions and the levels of care, or call to be connected with a licensed eating disorder treatment program that can assess what is going on and recommend a path forward.